ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/aop/article-10.6004-jnccn.2020.7610/article-10.6004-jnccn.2020.7610.xmlConsiderations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic2021-02-07https://harbor.dev.pubfactory.com/view/journals/jnccn/aop/article-10.6004-jnccn.2020.7610/article-10.6004-jnccn.2020.7610.pdf2021-02-08Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemichttps://harbor.dev.pubfactory.com/view/journals/jnccn/aop/article-10.6004-jnccn.2020.7639/article-10.6004-jnccn.2020.7639.xmlTelemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond2021-02-07https://harbor.dev.pubfactory.com/view/journals/jnccn/aop/article-10.6004-jnccn.2020.7639/article-10.6004-jnccn.2020.7639.pdf2021-02-08Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond